AACR21: CHRONOS-3 – copanlisib–rituximab combination therapy reduces risk of lymphoma progression or death by 48%

Written by Louis Gautier, Future Science Group

Copanlisib

The final analysis of the Phase III CHRONOS-3 trial, recently presented at the AACR Annual Meeting 2021 (9–14 April), demonstrates that copanlisib–rituximab combination therapy reduces the risk of disease progression or death by 48% in indolent non-Hodgkin lymphoma. Rituximab (Mabthera®) given as monotherapy has long been the standard of care in patients with relapsed indolent lymphomas of many subtypes, but it’s efficacy can be infrequent, and it does not produce long-term positive outcomes. Pre-clinical studies have demonstrated the importance of the PI3K signaling pathway in survival, activation of which plays a role in rituximab resistance. Earlier studies using the daily...

To view this content, please register now for access

It's completely free